Biblio

5 resultats trouvés
Filtres: Mot-clé is Sofosbuvir  [Clear All Filters]
D
Hezode C, Lebray P, de Ledinghen V, Zoulim F, Di Martino V, Boyer N, Larrey D, Botta-Fridlund D, Silvain C, Fontaine H et al..  2017.  Daclatasvir plus sofosbuvir, with or without ribavirin, for hepatitis C virus genotype 3 in a French early access programme. LIVER INTERNATIONAL. 37:1314-1324.
E
Rosenthal E., Fougerou-Leurent C., Renault A., Carrieri M.P, Marcellin F., Garraffo R., Teicher E., Aumaitre H., Lacombe K., Bailly F. et al..  2018.  Efficacy, safety and patient-reported outcomes of ledipasvir/sofosbuvir in NS3/4A protease inhibitor-experienced individuals with hepatitis C virus genotype 1 and HIV coinfection with and without cirrhosis (ANRS HC31 SOFTRIH study). HIV MEDICINE. 19:227-237.
M
Coilly A, Fougerou-Leurent C, de Ledinghen V, Houssel-Debry P, Duvoux C, Di Martino V, Radenne S, Kamar N, d'Alteroche L, Leroy V et al..  2016.  Multicentre experience using daclatasvir and sofosbuvir to treat hepatitis C recurrence - The ANRS CUPILT study. JOURNAL OF HEPATOLOGY. 65:711-718.
P
Desnoyer A, Pospai D, Le MPatrick, Gervais A, Heurgue-Berlot A, Laradi A, Harent S, Pinto A, Salmon D, Hillaire S et al..  2016.  Pharmacokinetics, safety and efficacy of a full dose sofosbuvir-based regimen given daily in hemodialysis patients with chronic hepatitis C. JOURNAL OF HEPATOLOGY. 65:40-47.
S
Pol S, Bourliere M, Lucier S, Hezode C, Dorival C, Larrey D, Bronowicki J-P, Ledinghen VDE, Zoulim F, Tran A et al..  2017.  Safety and efficacy of daclatasvir-sofosbuvir in HCV genotype 1-mono-infected patients. JOURNAL OF HEPATOLOGY. 66:39-47.